Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats

European Surgical Research

Volumn 34, Issue 5, 2002, Pages 351-356

  Korenaga, Daisuke ^a   Honda, M ^a   Yasuda, M ^a   Inutsuka, S ^a   Nozoe, T ^a   Tashiro, H ^a  

^a FUKUOKA DENTAL COLLEGE   (Japan)

Author keywords

5 Fluorouracil; Chemotherapy; Intestinal permeability; Oxonic acid; S 1; Tegafur

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL; HERMES ANTIGEN; LACTULOSE; MANNITOL; OXONATE POTASSIUM; TEGAFUR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; FOOD; GASTROINTESTINAL TOXICITY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE FUNCTION; INTESTINE MUCOSA PERMEABILITY; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE; URINARY EXCRETION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; FLUOROURACIL; GASTRIC MUCOSA; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MALE; OXONIC ACID; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TEGAFUR;

EID: 0036392102     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064001     Document Type: Article

References (21)

1. Kaufman S: 5-Fluorouracil in the treatment of gastrointestinal neoplasia. N Eng J Med 1973;288:199-201.
2. Comis RI, Carter SK: A review of chemotherapy in gastric cancer. Cancer 1974;34:1576-1586.
3. Fujii S, Ikenaka K, Fukushima M, Shirasaka T: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978;69:763-772.
4. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Umei N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-2606.
5. Takechi T, Nakano K, Uchida J, Miwa A, Toko K, Takeda S, Umei N, Shirasaka T: Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997;39:205-211.
6. Tatsumi K, Fukushima M, Shirasaka T, Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives of 5-fluorouracil degradation in rat liver extracts. Gann 1987;78:748-755.
7. Shirasaka T, Sakamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-4009.
8. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 1999;57:202-210.
9. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
10. Bijlsma PB, Peeters RA, Groot JA, Dekker PR, Taminiau JA, van der Meer R: Differential in vivo and in vitro intestinal permeability to lactulose and mannitol in animals and humans: A hypothesis. Gastroenterology 1995;108:687-696.
11. Shippee RL, Johnson AA, Cioffi WG, Lasko J, LeVoyer TE, Jordan BS: Simultaneous determination of lactulose and mannitol in urine of burn patients by gas-liquid chromatography. Clin Chem 1992;38:343-345.
12. Serizawa H, Miura S, Tashiro H, Imaeda H, Shiozaki H, Ohkubo N, Kimura H, Tanaka S, Tsuchiya M: Alteration of mucosal immunity after long-term ingestion of an elemental diet in rats. JPEN J Parenter Enteral Nutr 1994;18:141-147.
13. Kawahara K, Yoshino T, Kawasaki N, Miyake K, Akagi T: Abnormal expression of the human CD44 gene in early colorectal malignancy with special reference to variant exon 9 (9v). J Clin Pathol 1996;49:478-481.
14. Matsushima E, Yoshida K, Kitamura R, Yoshida K: Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1997;691:95-104.
15. Toh Y, Korenaga D, Maekawa S, Matsumata T, Muto Y, Ikeda T, Sugimachi K: Assessing the permeability of the gastrointestinal mucosa after oral administration of phenolsulfonphthalein. Hepatogastroenterology 1997;44:1147-1151.
16. Inutsuka S, Takesue F, Yasuda M, Honda M, Nagahama S, Kusumoto H, Nozoe T, Korenaga D: Assessment of the intestinal permeability following postoperative chemotherapy for human malignant disease (personal commun.).
17. Nagahama S, Korenaga D, Honda M, Inutsuka S, Sugimachi K: Assessment of the intestinal permeability after a gastrectomy and the oral administration of anticancer drugs in rats: Nitric oxide release in response to gut injury. Surgery 2002;131(1 Suppl):92-97.
18. Mihas AA, Toussaint J, Hsu HS, Dotherow P, Achord JL: Spontaneous bacterial peritonitis in cirrhosis: Clinical and laboratory features, survival and prognostic indicators. Hepatogastroenterology 1992;39:520-522.
19. Edmiston CE Jr, Condon RE: Bacterial translocation. Surg Gynecol Obstet 1991;173:73-83.
20. Parrilli G, Iaffaioli RV, Martorano M, Cuomo R, Tafuto S, Zampino MG, Budillon G, Bianco AR: Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer. Cancer Res 1989;49:3689-3691.
21. Heel K, Blennerhassett L, Kong SE, McCauley R, Hall J: Influence of ischaemia-reperfusion injury on CD44 expression in rat small intestine. Br J Surg 1998;85:1086-1089.